Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoepitope-specific T cells in Hematologic Malignancies
NCT06904066Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of TCR-transduced peripheral blood lymphocytes in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and 3 more (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety at 5 years. Started Oct 2026; status: recruiting.
02
Drugs
TCR-transduced peripheral blood lymphocytes
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06904066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904066.